Algernon Pharmaceuticals (XCNQ:AGN) Long-Term Capital Lease Obligation : C$0.00 Mil (As of Nov. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Long-Term Capital Lease Obligation?

Algernon Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Nov. 2023 was C$0.00 Mil.

Algernon Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Algernon Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Long-Term Capital Lease Obligation Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

Algernon Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	-	-

Algernon Pharmaceuticals (XCNQ:AGN) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Algernon Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals (XCNQ:AGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

AGNPF:USA AGW0:Germany

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals (XCNQ:AGN) Headlines

No Headlines